Comparative Trials Urged By NEJM Departing Editor To Deter "Me-Too" Drugs
Executive Summary
FDA should make new drug approvals based on comparisons to existing therapies in order to stem the tide of "me-too" medications being brought to market, New England Journal of Medicine Editor-In-Chief Marcia Angell, MD, said in the journal's June 22 issue.
You may also be interested in...
BMS Counting On Initial Combo Use For Glucovance To Supplant Glucophage
Bristol-Myers Squibb's Glucovance (metformin/glyburide) is emerging from FDA in time to give Bristol a half a year or more to transfer the market from its $1.9 bil. single-agent product Glucophage to the new combo.
BMS Counting On Initial Combo Use For Glucovance To Supplant Glucophage
Bristol-Myers Squibb's Glucovance (metformin/glyburide) is emerging from FDA in time to give Bristol a half a year or more to transfer the market from its $1.9 bil. single-agent product Glucophage to the new combo.
Drug Pricing Strategies To Be Discussed At HHS Drug Conference In August
The pharmaceutical industry's methods for arriving at drug prices will be considered at an HHS conference in August.